Friday, September 4, 2026
27.2 C
Bengaluru

IQVIA Sponsors Race for 7 to Commemorate World Rare Disease Day

#IQVIA Sponsors Race for 7 to commemorate World Rare Disease Day

“IQVIA is delighted to be associated for the fourth consecutive year as the main sponsor of Race for 7. While rare diseases, by virtue of their definition, affect relatively fewer number of patients, the overall number of rare disease patients is large enough to warrant more focused attention.

We hope that the public will come forward in large numbers to participate in Race for 7 and help amplify the voice of the rare disease community. Race for 7 is a unique way of engaging the community with those who matter most – patients and their caregivers for a common cause,” said Amit Mookim, Managing Director, IQVIA – South Asia.

Rare Diseases is a key therapeutic focus for IQVIA who has provided clinical services for more than 258 rare disease studies in 87 countries worldwide since 2011.

Race for 7 is held simultaneously in multiple cities and two countries – India and the USA. Over the years, the run has expanded and in 2019 it will be conducted over February and March across 13 Indian cities – Bengaluru, Mysuru, Chennai, Kolkata, Mumbai, Jaipur, Coimbatore, Bikaner, Hyderabad, New Delhi, Ahmedabad, Thiruvananthapuram, Kochi.

– MedicinMan Press Release

Hot this week

Pharmacy of the World Pricing Paradox

India occupies an extraordinary position in global pharmaceuticals. It...

Why The Government Must Stop Playing Market Trader And Start Being The Sheriff

India has two very different pharmaceutical regulators living inside...

MedicinMan Pharma Pulse: August 2026

🚀 The Mega-Merger That Wasn't Early August saw the...

GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?

STOP PRESS August 10, 2026: Regulatory Authorisation — The UK...

How To See Dr Reddy’s Nestle In The Wellness Shift

GLP-1 medicines such as semaglutide and tirzepatide are changing...

Topics

Pharmacy of the World Pricing Paradox

India occupies an extraordinary position in global pharmaceuticals. It...

Why The Government Must Stop Playing Market Trader And Start Being The Sheriff

India has two very different pharmaceutical regulators living inside...

MedicinMan Pharma Pulse: August 2026

🚀 The Mega-Merger That Wasn't Early August saw the...

GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?

STOP PRESS August 10, 2026: Regulatory Authorisation — The UK...

How To See Dr Reddy’s Nestle In The Wellness Shift

GLP-1 medicines such as semaglutide and tirzepatide are changing...

How To Power The India Biopharma Regulatory Revolution Now

Beyond the Pharmacy of the World: Why India's Biopharma...

Will Mounjaro Disrupt Existing Therapy Areas Like Cardiology?

Something remarkable has happened in the Indian pharmaceutical market....

Can India Pivot From Low-Cost Medical Tourism to Trusted Medical Value Travel?

C-Suite Executive Summary India stands at a pivotal juncture in...
spot_img

Related Articles

spot_imgspot_img